The Center on Alcohol, Substance Use, and Addictions (CASAA) investigator Frank Schwebel, Ph.D., is collaborating with a mobile company on a new study. The Mindfulness and Medication Adherence (MiMA) Study is a digital intervention aimed at supporting individuals taking medications for opioid use disorder and chronic pain. This project uses digital health to provide a behavioral health intervention based on Mindfulness-Based Relapse Prevention (MBRP) and Acceptance and Commitment Therapy (ACT).
Schwebel explained that the goals are to improve treatment outcomes by offering a tailored digital health intervention that boosts medication adherence rates, reduces cravings and withdrawal symptoms, and aids individuals in managing chronic pain. The project gathers real-time data through ecological momentary assessment (EMA) to understand better how this digital intervention affects participant behaviors and health.
“We’re leveraging innovative, evidence-based digital tools to extend behavioral health support beyond traditional care environments,” Schwebel stated. “This is particularly important for people struggling with access to care or facing long-term episodes of care like people with chronic pain and opioid use disorder.”
The project receives funding from the National Institute on Drug Abuse, with the intervention developed in collaboration between Schwebel at CASAA and MEMOTEXT, a digital health company specializing in personalized communication for behavior change.
